RAKOVINA THERAPEUTICS INC (RKV.CA) Stock Income Statement
TSX-V:RKV - CA75103L1013 - Common Stock
0.5 CAD
0 (0%)
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 5.21M | 3.79M | 2.48M | 2.82M | 2.48M | |||
| Research and Development | 2.25M | 1.80M | 1.14M | 1.41M | 1.50M | |||
| Selling, General, and Administrative Expenses | 2.26M | 1.36M | 810.40K | 868.30K | 970.00K | |||
| Operating Income | -5.21M | -3.79M | -2.48M | -2.82M | -2.48M | |||
| Interest Income/Expense | -273.00K | -265.80K | -87.00K | 26.30K | 0.00 | |||
| Other Income/Expense | N/A | N/A | -43.80K | N/A | N/A | |||
| Non Recurring Items | N/A | -18.80K | N/A | 0.00 | -3.05M | |||
| Income Before Taxes | -5.50M | -4.07M | -2.61M | -2.79M | -5.52M | |||
| Net Income | -5.50M | -4.07M | -2.61M | -2.79M | -5.52M | |||
| EBITDA | -4.67M | -3.25M | -1.95M | -2.28M | -2.07M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.53 | -0.49 | -0.37 | -0.40 | -1.02 | |||
| Statistics | ||||||||
All data in CAD